Novartis’s New Eye Treatment Beovu Gets CHMP Nod
Mounts Challenge to Eylea
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.